Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2023 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on...
July 24, 2023 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
July 06, 2023 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million...
June 12, 2023 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas...
June 07, 2023 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will...
June 01, 2023 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion...
May 31, 2023 08:00 ET | Source: Myriad Genetics, Inc.

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP,...
May 24, 2023 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...
May 08, 2023 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Earns 2023 Great Place to Work Certification™

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work®...
May 03, 2023 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer...